04 欧洲多国即将恢复接种牛津/阿斯利康疫苗

在欧洲药品管理局得出结论称牛津/阿斯利康疫苗“安全有效”后，德国、法国、意大利和西班牙表示将恢复该疫苗的接种工作。

全文共757个词，by Donato Paolo Mancini in Rome

Germany, France, Italy and Spain said they would resume using the Oxford/AstraZeneca coronavirus vaccine after the EU drugs regulator said there was a “clear scientific conclusion” that the jab was “safe and effective”.

德国、法国、意大利和西班牙表示，它们将恢复接种牛津（Oxford）/阿斯利康（AstraZeneca）新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）疫苗。此前，欧盟（EU）药品监管机构表示，有“明确的科学结论”证明该疫苗“安全有效”。

Emer Cooke, head of the European Medicines Agency, on Thursday said its investigation had concluded that the AstraZeneca vaccine was “not associated” with a potential risk of blood clots noted recently by some scientists, adding that the benefits of the shot outweighed possible risks.

欧洲药品管理局（EMA）局长埃默·库克（Emer Cooke）周四表示，该局的调查已得出结论，阿斯利康疫苗与一些科学家最近指出的出现血凝的潜在风险“没有关联”，并补充称，接种该疫苗的益处大过可能的风险。

“If it were me, I would be vaccinated tomorrow,” said Cooke.

“如果换成我，我明天就会去接种。”库克说。

EMA officials said they could not “definitively” rule out a link between the vaccine and a rarer, and more serious, type of blood clot associated with a low platelet count. “A causal link with the vaccine is not proven, but is possible and deserves further analysis,” the agency said. Cooke recommended an awareness campaign that aimed to “spot and mitigate any possible side effects” of the vaccine.

欧洲药品管理局的官员表示，他们无法“绝对”排除这款疫苗与一种更罕见、更严重，且伴随血小板数量下降的血凝现象之间的关联。该机构表示：“与该疫苗之间的因果联系尚未得到证实，但是有可能的，值得进一步分析。”库克建议开展一场认知运动，目标是“发现并减轻（该疫苗的）任何可能的副作用”。

Mario Draghi, prime minister of Italy, which was among the countries to suspend use of the AstraZeneca vaccine, said it would resume using the shot on Friday.

意大利总理马里奥·德拉吉（Mario Draghi）表示，该国将于周五恢复接种阿斯利康疫苗。意大利是暂停使用这款疫苗的国家之一。

Jean Castex, prime minister of France, said his country would do the same, adding he would also receive the jab “to show that we can all have total confidence”.

法国总理让·卡斯泰（Jean Castex）称法国也将这样做，并补充称，他自己也将接种阿斯利康疫苗，“以显示我们都对其完全有信心”。

Germany’s health minister Jens Spahn announced AstraZeneca vaccinations would restart on Friday. He said it was good news the jab had been cleared but stood by the decision to suspend its use.

德国卫生部长延斯·施潘（Jens Spahn）宣布，阿斯利康疫苗的接种工作将于周五重新启动。他表示，该疫苗受到的质疑被澄清是好消息，但坚持暂停使用的决定没有错。

“EMA’s analysis confirmed our approach. It was important to suspend vaccinations with [AstraZeneca] as a precaution until the conspicuous cluster of cases of this very rare thrombosis had been analysed,” he said. “It would have been irresponsible to let doctors continue to vaccinate people without this information in our view.”

“欧洲药品管理局的分析肯定了我们的做法。在对这种非常罕见的血栓形成病例的明显集中出现进行分析之前，暂停接种（阿斯利康疫苗）作为预防措施非常重要。”他说，“在没有得到这些信息的情况下让医生继续为人们接种这款疫苗是不负责任的。”

Spain said it would resume administering Oxford/AstraZeneca vaccines as of Wednesday next week. Carolina Darias, health minister, said this timing would allow the country’s health authorities to reconsider who should receive the vaccine. Madrid previously banned the use of the vaccine for over-55s — a decision it had been due to review when the controversy about thrombosis began.

西班牙表示，将从下周三开始恢复接种牛津/阿斯利康疫苗。西班牙卫生部长卡罗琳娜·达里亚斯（Carolina Darias）表示，这个时间选择可以让该国的卫生部门重新考虑哪些人群应该接种这款疫苗。马德里此前禁止为55岁以上人群接种该疫苗——其本要重新评估这一决定，恰在此时爆发了围绕引发血栓的争论。

Irish health authorities welcomed the EMA decision and said they would be “deliberating” the findings on Thursday night and Friday morning.

爱尔兰卫生部门对欧洲药品管理局的决定表示欢迎，并称将在周四晚间和周五上午“审议”调查结果。

The suspensions this week by more than a dozen European countries including Germany and Spain dealt a fresh blow to the continent’s ailing vaccination campaign.

包括德国和西班牙在内的十几个欧洲国家本周暂停接种阿斯利康疫苗的决定，对欧洲大陆艰难推进的疫苗接种运动造成了新的打击。

While countries including Austria had put their programmes on hold, the wider suspension came after German researchers noted an apparent raised incidence of rare blood clots that led Berlin to halt the AstraZeneca element of its inoculation programme.

虽然包括奥地利在内的一些国家先暂停了接种计划，但更大范围的暂停出现在德国研究人员发现罕见的血凝现象发生率明显上升、导致柏林方面在本国的接种计划中暂停使用阿斯利康疫苗之后。

The UK drugs regulator on Thursday said five such clots had been recorded in Britain in those administered with the vaccine, but stressed that no link had been established. It also urged people to continue to take the vaccine.

英国药品监管机构周四表示，在英国接种阿斯利康疫苗的人群中发现了五例这种血凝病例，但强调称，没有确定上述病例与该疫苗存在联系。该机构还敦促人们继续接种这款疫苗。

The AstraZeneca jab has faced multiple challenges. Early data generated by clinical trials were criticised by some experts as being inconsistent. Some European nations also limited use of the vaccine in some age groups, citing a lack of population-specific data.

阿斯利康疫苗正面临多重挑战。一些专家批评临床试验早期数据不一致。一些欧洲国家还限制某些年龄群体使用该疫苗，理由是缺乏特定人群的数据。

Those fears had eased in recent weeks thanks to the successful rollout of the jab to 25m people.

最近几周，此类担忧有所缓解，原因是阿斯利康疫苗已经在2500万人身上成功接种。

AstraZeneca welcomed the result of the assessment. Its chief medical officer, Ann Taylor, said: “We trust that, after the regulators’ careful decisions, vaccinations can once again resume across Europe.”

阿斯利康对欧洲药品管理局的评估结果表示欢迎。该公司首席医疗官安·泰勒（Ann Taylor）表示：“我们相信，在各国监管机构做出慎重决定之后，疫苗接种工作可以再次在欧洲各地恢复。”

Additional reporting by Miles Johnson in Rome, Leila Abboud in Paris and Dan Dombey in Madrid and Guy Chazan in Berlin

迈尔斯·约翰逊（Miles Johnson）罗马、莱拉·阿布德（Leila Abboud）巴黎、丹·董贝（Dan Dombey）马德里、盖伊·查赞（Guy Chazan）柏林补充报道